Ensysce Biosciences Ownership

ENSC Stock  USD 3.67  1.80  96.26%   
Roughly 90.82 percent of Ensysce Biosciences outstanding shares are held by general public with 0.62 (percent) owned by insiders and only 8.56 % by other corporate entities.
Some institutional investors establish a significant position in stocks such as Ensysce Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ensysce Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

Ensysce Stock Ownership Analysis

The company has price-to-book (P/B) ratio of 0.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ensysce Biosciences recorded a loss per share of 11.45. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 6th of December 2024. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Ensysce Biosciences call Lynn Kirkpatrick at 858 263 4196 or check out https://www.ensysce.com.

Ensysce Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ensysce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Lynn Kirkpatrick over a month ago
Acquisition by Lynn Kirkpatrick of 263400 shares of Ensysce Biosciences at 3.19 subject to Rule 16b-3
 
Martin Steven Robert over a month ago
Acquisition by Martin Steven Robert of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3
 
Carrera Eric over a month ago
Disposition of 8330 shares by Carrera Eric of Ensysce Biosciences subject to Rule 16b-3
 
Gower Bob G over two months ago
Acquisition by Gower Bob G of 7919026 shares of Ensysce Biosciences subject to Rule 16b-3
 
Wright Richard Chester over three months ago
Acquisition by Wright Richard Chester of 49975 shares of Ensysce Biosciences subject to Rule 16b-3
 
Martin Steven Robert over three months ago
Acquisition by Martin Steven Robert of 15000 shares of Ensysce Biosciences subject to Rule 16b-3
 
Silvers Daniel B. over three months ago
Disposition of 359869 shares by Silvers Daniel B. of Ensysce Biosciences subject to Rule 16b-3
 
Weil A Lorne over three months ago
Acquisition by Weil A Lorne of 730110 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3
 
Carrera Eric over six months ago
Acquisition by Carrera Eric of 30000 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3
 
Gower Bob G over six months ago
Acquisition by Gower Bob G of 270000 shares of Ensysce Biosciences at 0.4777 subject to Rule 16b-3
 
Birkett Kevin Geoffrey over six months ago
Acquisition by Birkett Kevin Geoffrey of 329250 shares of Ensysce Biosciences at 2.59 subject to Rule 16b-3
 
Weinstein David L. over six months ago
Disposition of tradable shares by Weinstein David L. of Ensysce Biosciences subject to Rule 16b-3

Ensysce Biosciences Outstanding Bonds

Ensysce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ensysce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ensysce bonds can be classified according to their maturity, which is the date when Ensysce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.